

Impaired factor XIII activation in patients with congenital afibrinogenemia

Françoise Bridey,¹ Claude Négrier,² Cedric Duval,³ Robert Ariëns,³ Philippe de Moerloose⁴ and Alessandro Casini⁵

¹Clinical Development, Laboratoire Français du Fractionnement et des Biotechnologies (LFB), Les Ulis, France; ²Hemostasis Unit, Hematology Division, Louis Pradel University Hospital, University Claude Bernard, Lyon, France; ³Thrombosis and Tissue Repair Group, Department of Discovery and Translational Science, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, UK; ⁴Faculty of Medicine, University Hospitals of Geneva, Switzerland and ⁵Division of Angiology and Haemostasis, Faculty of Medicine, University Hospitals of Geneva, Switzerland


*Correspondence: FRANÇOISE BRIDEY - bridey@lfb.fr
doi:10.3324/haematol.2018.203901*

Supplementary data

Legend Supplementary Figure 1.

Correlation between the FXIII activity and the functional fibrinogen before and after fibrinogen concentrate infusion

Supplementary Figure 1. Scatterplot of FXIII activity versus fibrinogen activity



R: Coefficient of Pearson

Legend Supplementary Figure 2.

Kinetics of FXIII cross-linking activity after activation of citrated plasma, as measured by biotinylated pentylamine incorporation into casein-coated plates. Black line: control (normal plasma); Grey lines: six afibrinogenemic patients.

Supplementary Figure 2. Time course of FXIII activity after activation

